MyFinsight
Home
Blog
About
Net income
$144,400K
(25.13%↑ Y/Y)
Proceeds from borrowings
under revolving...
$600,000K
Other assets and
liabilities, net
-$78,800K
(-209.02%↓ Y/Y)
Stock-based compensation
$65,000K
(-38.45%↓ Y/Y)
Amortization of acquired
intangible assets
$16,400K
(720.00%↑ Y/Y)
Depreciation
$8,400K
(-34.88%↓ Y/Y)
Realized loss on sale of
available-for-sale debt securities
-$5,200K
Amortization of inventory
fair-value step-up
$3,000K
Non-cash lease expense
$900K
(-93.71%↓ Y/Y)
Issuances of common stock
under benefit plans
$84,800K
(82.37%↑ Y/Y)
Cash flows from
operating activities
$136,400K
(-18.23%↓ Y/Y)
Cash flows from
financing activities
$63,400K
(152.31%↑ Y/Y)
Canceled cashflow
$185,700K
Canceled cashflow
$621,400K
Change in cash, cash
equivalents and restricted...
$64,400K
(107.74%↑ Y/Y)
Canceled cashflow
$135,400K
Accounts receivable
$84,300K
(-27.70%↓ Y/Y)
Income tax assets and
liabilities
-$59,600K
Deferred income taxes
-$25,300K
(50.49%↑ Y/Y)
Accounts payable and
accrued liabilities
-$8,500K
(-130.47%↓ Y/Y)
Inventory
$6,500K
(1725.00%↑ Y/Y)
Changes in fair values of
equity investments
$1,200K
(103.22%↑ Y/Y)
Accretion of discount on
available-for-sale debt...
$300K
(-96.25%↓ Y/Y)
Sales and maturities
of...
$2,268,300K
(280.14%↑ Y/Y)
Repayments of borrowings
under revolving...
$600,000K
Repurchases of common stock
$12,000K
(-92.84%↓ Y/Y)
Payment of debt issuance
costs
$6,700K
Taxes paid related to
net share...
$2,700K
Cash flows from
investing activities
-$135,400K
(-814.86%↓ Y/Y)
Canceled cashflow
$2,268,300K
Acquisition of business, net
of cash acquired
$2,358,500K
Purchases of
available-for-sale debt securities
$37,400K
(-93.64%↓ Y/Y)
Capital expenditures
$7,800K
(-66.38%↓ Y/Y)
Back
Back
Cash Flow
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)
source: myfinsight.com